市場調査レポート

商品コード

1442840

転移性骨疾患市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年～2031年

Metastatic Bone Disease Market (Treatment: Medication, Radiation Therapy, Surgical Intervention, and Tumor Ablation Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

出版日: 2024年01月08日 | 発行: Transparency Market Research

| ページ情報: 英文 202 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 5,795 910,626円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Multi-user License)

USD 8,795 1,382,046円

レポートPDFを同一の部署内・課内の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Corporate License)

USD 11,795 1,853,466円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

転移性骨疾患市場 - レポートの範囲

世界の転移性骨疾患市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、 2023年を基準年、2031年を予測年とみなして、2017年から2031年までの世界の転移性骨疾患の収益を提供します。このレポートは、2023年から2031年までの世界の転移性骨疾患市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、転移性骨疾患市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界の転移性骨疾患市場の競合情勢を詳しく掘り下げています。世界の転移性骨疾患市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、SWOTは、このレポートで紹介されている世界の転移性骨疾患市場のプレーヤーの属性です。

市場企業 - 競合マトリックス（企業の階層および規模別）
市場シェア分析：企業別（2022年）
企業プロファイル
- Amgen, Inc.
- Merck &Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Eli Lilly and Company
- Bayer AG
- Fresenius Kabi AG
- Boston Scientific Corporation
- Medtronic

図表

List of Tables

Table 01: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 02: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
Table 03: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
Table 04: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 08: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
Table 09: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
Table 10: North America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 11: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 13: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
Table 14: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
Table 15: Europe Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 18: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
Table 19: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
Table 20: Asia Pacific Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 23: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
Table 24: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
Table 25: Latin America Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031
Table 26: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Treatment, 2017-2031
Table 28: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Origin of Metastasis, 2017-2031
Table 29: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by Provider Type, 2017-2031
Table 30: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

Figure 01: Global Metastatic Bone Disease Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Treatment, 2022
Figure 03: Global Metastatic Bone Disease Market Value Share, by Treatment, 2022
Figure 04: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Origin of Metastasis, 2022
Figure 05: Global Metastatic Bone Disease Market Value Share, by Origin of Metastasis, 2022
Figure 06: Global Metastatic Bone Disease Market Revenue (US$ Mn), by Provider Type, 2022
Figure 07: Global Metastatic Bone Disease Market Value Share, by Provider Type, 2022
Figure 08: Global Metastatic Bone Disease Market Value Share, by End-user, 2022
Figure 09: Global Metastatic Bone Disease Market Value Share, by End-user, 2022
Figure 10: Global Metastatic Bone Disease Market Value Share, by Region, 2022
Figure 11: Global Metastatic Bone Disease Market Value (US$ Mn) Forecast, 2017-2031
Figure 12: Global Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 13: Global Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 14: Global Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 15: Global Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
Figure 16: Global Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 17: Global Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
Figure 18: Global Metastatic Bone Disease Market Revenue (US$ Mn), by End-user, 2022
Figure 19: Global Metastatic Bone Disease Market Value Share, by End-user, 2022
Figure 20: Global Metastatic Bone Disease Market Value Share Analysis, by Region, 2022 and 2031
Figure 21: Global Metastatic Bone Disease Market Attractiveness Analysis, by Region, 2023-2031
Figure 22: North America Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 23: North America Metastatic Bone Disease Market Attractiveness Analysis, by Country, 2023-2031
Figure 24: North America Metastatic Bone Disease Market Value Share Analysis, by Country, 2022 and 2031
Figure 25: North America Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 26: North America Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 27: North America Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 28: North America Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
Figure 29: North America Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 30: North America Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
Figure 31: North America Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
Figure 32: North America Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023-2031
Figure 33: Europe Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 34: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 35: Europe Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Europe Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 37: Europe Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 38: Europe Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 39: Europe Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
Figure 40: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 41: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
Figure 42: Europe Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
Figure 43: Europe Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023-2031
Figure 44: Asia Pacific Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023-2031
Figure 45: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 46: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 47: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 48: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 49: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 50: Asia Pacific Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
Figure 51: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2017-2031
Figure 52: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
Figure 53: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
Figure 54: Asia Pacific Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023-2031
Figure 55: Latin America Metastatic Bone Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 56: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 57: Latin America Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 58: Latin America Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 59: Latin America Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 60: Latin America Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 61: Latin America Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
Figure 62: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 63: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
Figure 64: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
Figure 65: Latin America Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023-2031
Figure 66: Middle East & Africa Metastatic Bone Disease Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 67: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 68: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 69: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Treatment, 2022 and 2031
Figure 70: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Origin of Metastasis, 2022 and 2031
Figure 71: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by Provider Type, 2022 and 2031
Figure 72: Middle East & Africa Metastatic Bone Disease Market Value Share Analysis, by End-user, 2022 and 2031
Figure 73: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Treatment, 2023-2031
Figure 74: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Origin of Metastasis, 2023-2031
Figure 75: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by Provider Type, 2023-2031
Figure 76: Middle East & Africa Metastatic Bone Disease Market Attractiveness Analysis, by End-user, 2023-2031

Product Code: TMRGL37802

Metastatic Bone Disease Market - Scope of Report

TMR's report on the global metastatic bone disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global metastatic bone disease market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global metastatic bone disease market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the metastatic bone disease market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global metastatic bone disease market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global metastatic bone disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global metastatic bone disease market.

The report delves into the competitive landscape of the global metastatic bone disease market. Key players operating in the global metastatic bone disease market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global metastatic bone disease market profiled in this report.

Key Questions Answered in Global metastatic bone disease Market Report:

What is the sales/revenue generated by metastatic bone disease across all regions during the forecast period?
What are the opportunities in the global metastatic bone disease market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Metastatic Bone Disease Market - Research Objectives and Research Approach

The comprehensive report on the global metastatic bone disease market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global metastatic bone disease market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global metastatic bone disease market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Metastatic Bone Disease Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Metastatic Bone Disease Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Metastatic Bone Disease Market Analysis and Forecast, by Treatment

6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment, 2017-2031
- 6.3.1. Medication
  - 6.3.1.1. Chemotherapy
  - 6.3.1.2. Hormone Therapy
  - 6.3.1.3. Bisphosphonates
  - 6.3.1.4. Opiate Therapy
  - 6.3.1.5. Immunotherapy
- 6.3.2. Radiation Therapy
- 6.3.3. Surgical Intervention
- 6.3.4. Tumor Ablation Therapy
6.4. Market Attractiveness, by Treatment

7. Global Metastatic Bone Disease Market Analysis and Forecast, by Origin of Metastasis

7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Origin of Metastasis, 2017-2031
- 7.3.1. Breast
- 7.3.2. Lung
- 7.3.3. Thyroid
- 7.3.4. Kidney
- 7.3.5. Prostate
- 7.3.6. Others
7.4. Market Attractiveness, by Origin of Metastasis

8. Global Metastatic Bone Disease Market Analysis and Forecast, by Provider Type

8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Provider Type, 2017-2031
- 8.3.1. OEM
- 8.3.2. Non-OEM
8.4. Market Attractiveness, by Provider Type

9. Global Metastatic Bone Disease Market Analysis and Forecast, by End-user

9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
- 9.3.1. Hospitals
- 9.3.2. Specialty Clinics
- 9.3.3. Ambulatory Surgical Centers
9.4. Market Attractiveness, by End-user

10. Global Metastatic Bone Disease Market Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Metastatic Bone Disease Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017-2031
- 11.2.1. Medication
  - 11.2.1.1. Chemotherapy
  - 11.2.1.2. Hormone Therapy
  - 11.2.1.3. Bisphosphonates
  - 11.2.1.4. Opiate Therapy
  - 11.2.1.5. Immunotherapy
- 11.2.2. Radiation Therapy
- 11.2.3. Surgical Intervention
- 11.2.4. Tumor Ablation Therapy
11.3. Market Attractiveness, by Treatment
11.4. Market Value Forecast, by Origin of Metastasis, 2017-2031
- 11.4.1. Breast
- 11.4.2. Lung
- 11.4.3. Thyroid
- 11.4.4. Kidney
- 11.4.5. Prostate
- 11.4.6. Others
11.5. Market Attractiveness, by Origin of Metastasis
11.6. Market Value Forecast, by Provider Type, 2017-2031
- 11.6.1. OEM
- 11.6.2. Non-OEM
11.7. Market Attractiveness, by Provider Type
11.8. Market Value Forecast, by End-user
- 11.8.1. Hospitals
- 11.8.2. Specialty Clinics
- 11.8.3. Ambulatory Surgical Centers
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.10.1. U.S.
- 11.10.2. Canada
11.11. Market Attractiveness Analysis
- 11.11.1. By Treatment
- 11.11.2. By Origin of Metastasis
- 11.11.3. By Provider Type
- 11.11.4. By End-user
- 11.11.5. By Country

12. Europe Metastatic Bone Disease Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017-2031
- 12.2.1. Medication
  - 12.2.1.1. Chemotherapy
  - 12.2.1.2. Hormone Therapy
  - 12.2.1.3. Bisphosphonates
  - 12.2.1.4. Opiate Therapy
  - 12.2.1.5. Immunotherapy
- 12.2.2. Radiation Therapy
- 12.2.3. Surgical Intervention
- 12.2.4. Tumor Ablation Therapy
12.3. Market Attractiveness, by Treatment
12.4. Market Value Forecast, by Origin of Metastasis, 2017-2031
- 12.4.1. Breast
- 12.4.2. Lung
- 12.4.3. Thyroid
- 12.4.4. Kidney
- 12.4.5. Prostate
- 12.4.6. Others
12.5. Market Attractiveness, by Origin of Metastasis
12.6. Market Value Forecast, by Provider Type, 2017-2031
- 12.6.1. OEM
- 12.6.2. Non-OEM
12.7. Market Attractiveness, by Provider Type
12.8. Market Value Forecast, by End-user, 2017-2031
- 12.8.1. Hospitals
- 12.8.2. Specialty Clinics
- 12.8.3. Ambulatory Surgical Centers
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.10.1. Germany
- 12.10.2. U.K.
- 12.10.3. France
- 12.10.4. Italy
- 12.10.5. Spain
- 12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
- 12.11.1. By Treatment
- 12.11.2. By Origin of Metastasis
- 12.11.3. By Provider Type
- 12.11.4. By End-user
- 12.11.5. By Country/Sub-region

13. Asia Pacific Metastatic Bone Disease Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017-2031
- 13.2.1. Medication
  - 13.2.1.1. Chemotherapy
  - 13.2.1.2. Hormone Therapy
  - 13.2.1.3. Bisphosphonates
  - 13.2.1.4. Opiate Therapy
  - 13.2.1.5. Immunotherapy
- 13.2.2. Radiation Therapy
- 13.2.3. Surgical Intervention
- 13.2.4. Tumor Ablation Therapy
13.3. Market Attractiveness, by Treatment
13.4. Market Value Forecast, by Origin of Metastasis, 2017-2031
- 13.4.1. Breast
- 13.4.2. Lung
- 13.4.3. Thyroid
- 13.4.4. Kidney
- 13.4.5. Prostate
- 13.4.6. Others
13.5. Market Attractiveness, by Origin of Metastasis
13.6. Market Value Forecast, by Provider Type, 2017-2031
- 13.6.1. OEM
- 13.6.2. Non-OEM
13.7. Market Attractiveness, by Provider Type
13.8. Market Value Forecast, by End-user, 2017-2031
- 13.8.1. Hospitals
- 13.8.2. Specialty Clinics
- 13.8.3. Ambulatory Surgical Centers
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.10.1. China
- 13.10.2. Japan
- 13.10.3. India
- 13.10.4. Australia & New Zealand
- 13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
- 13.11.1. By Treatment
- 13.11.2. By Origin of Metastasis
- 13.11.3. By Provider Type
- 13.11.4. By End-user
- 13.11.5. By Country/Sub-region

14. Latin America Metastatic Bone Disease Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2017-2031
- 14.2.1. Medication
  - 14.2.1.1. Chemotherapy
  - 14.2.1.2. Hormone Therapy
  - 14.2.1.3. Bisphosphonates
  - 14.2.1.4. Opiate Therapy
  - 14.2.1.5. Immunotherapy
- 14.2.2. Radiation Therapy
- 14.2.3. Surgical Intervention
- 14.2.4. Tumor Ablation Therapy
14.3. Market Attractiveness, by Treatment
14.4. Market Value Forecast, by Origin of Metastasis, 2017-2031
- 14.4.1. Breast
- 14.4.2. Lung
- 14.4.3. Thyroid
- 14.4.4. Kidney
- 14.4.5. Prostate
- 14.4.6. Others
14.5. Market Attractiveness, by Origin of Metastasis
14.6. Market Value Forecast, by Provider Type, 2017-2031
- 14.6.1. OEM
- 14.6.2. Non-OEM
14.7. Market Attractiveness, by Provider Type
14.8. Market Value Forecast, by End-user, 2017-2031
- 14.8.1. Hospitals
- 14.8.2. Specialty Clinics
- 14.8.3. Ambulatory Surgical Centers
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.10.1. Brazil
- 14.10.2. Mexico
- 14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
- 14.11.1. By Treatment
- 14.11.2. By Origin of Metastasis
- 14.11.3. By Provider Type
- 14.11.4. By End-user
- 14.11.5. By Country/Sub-region

15. Middle East & Africa Metastatic Bone Disease Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment, 2017-2031
- 15.2.1. Medication
  - 15.2.1.1. Chemotherapy
  - 15.2.1.2. Hormone Therapy
  - 15.2.1.3. Bisphosphonates
  - 15.2.1.4. Opiate Therapy
  - 15.2.1.5. Immunotherapy
- 15.2.2. Radiation Therapy
- 15.2.3. Surgical Intervention
- 15.2.4. Tumor Ablation Therapy
15.3. Market Attractiveness, by Treatment
15.4. Market Value Forecast, by Origin of Metastasis, 2017-2031
- 15.4.1. Breast
- 15.4.2. Lung
- 15.4.3. Thyroid
- 15.4.4. Kidney
- 15.4.5. Prostate
- 15.4.6. Others
15.5. Market Attractiveness, by Origin of Metastasis
15.6. Market Value Forecast, by Provider Type, 2017-2031
- 15.6.1. OEM
- 15.6.2. Non-OEM
15.7. Market Attractiveness, by Provider Type
15.8. Market Value Forecast, by End-user, 2017-2031
- 15.8.1. Hospitals
- 15.8.2. Specialty Clinics
- 15.8.3. Ambulatory Surgical Centers
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.10.1. GCC Countries
- 15.10.2. South Africa
- 15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
- 15.11.1. By Treatment
- 15.11.2. By Origin of Metastasis
- 15.11.3. By Provider Type
- 15.11.4. By End-user
- 15.11.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
- 16.3.1. Amgen, Inc.
  - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.1.2. Product Portfolio
  - 16.3.1.3. Financial Overview
  - 16.3.1.4. SWOT Analysis
  - 16.3.1.5. Strategic Overview
- 16.3.2. Merck & Co., Inc.
  - 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.2.2. Product Portfolio
  - 16.3.2.3. Financial Overview
  - 16.3.2.4. SWOT Analysis
  - 16.3.2.5. Strategic Overview
- 16.3.3. F. Hoffmann-La Roche Ltd.
  - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.3.2. Product Portfolio
  - 16.3.3.3. Financial Overview
  - 16.3.3.4. SWOT Analysis
  - 16.3.3.5. Strategic Overview
- 16.3.4. Novartis AG
  - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.4.2. Product Portfolio
  - 16.3.4.3. Financial Overview
  - 16.3.4.4. SWOT Analysis
  - 16.3.4.5. Strategic Overview
- 16.3.5. Eli Lilly and Company
  - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.5.2. Product Portfolio
  - 16.3.5.3. Financial Overview
  - 16.3.5.4. SWOT Analysis
  - 16.3.5.5. Strategic Overview
- 16.3.6. Bayer AG
  - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.6.2. Product Portfolio
  - 16.3.6.3. Financial Overview
  - 16.3.6.4. SWOT Analysis
  - 16.3.6.5. Strategic Overview
- 16.3.7. Fresenius Kabi AG
  - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.7.2. Product Portfolio
  - 16.3.7.3. Financial Overview
  - 16.3.7.4. SWOT Analysis
  - 16.3.7.5. Strategic Overview
- 16.3.8. Boston Scientific Corporation
  - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.8.2. Product Portfolio
  - 16.3.8.3. Financial Overview
  - 16.3.8.4. SWOT Analysis
  - 16.3.8.5. Strategic Overview
- 16.3.9. Medtronic
  - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.9.2. Product Portfolio
  - 16.3.9.3. Financial Overview
  - 16.3.9.4. SWOT Analysis
  - 16.3.9.5. Strategic Overview

転移性骨疾患市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年～2031年

Metastatic Bone Disease Market (Treatment: Medication, Radiation Therapy, Surgical Intervention, and Tumor Ablation Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

転移性骨疾患市場 - レポートの範囲

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

第5章 重要な洞察

第6章 世界市場の分析と予測：治療法別

第7章 世界市場の分析と予測：転移の原因別

第8章 世界市場の分析と予測：プロバイダータイプ別

第9章 世界市場の分析と予測：エンドユーザー別

第10章 世界市場の分析と予測：地域別

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東・アフリカ市場の分析と予測

第16章 競合情勢

List of Tables

List of Figures

Metastatic Bone Disease Market - Scope of Report

Key Questions Answered in Global metastatic bone disease Market Report:

Metastatic Bone Disease Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Metastatic Bone Disease Market

4. Market Overview

5. Key Insights

6. Global Metastatic Bone Disease Market Analysis and Forecast, by Treatment

7. Global Metastatic Bone Disease Market Analysis and Forecast, by Origin of Metastasis

8. Global Metastatic Bone Disease Market Analysis and Forecast, by Provider Type

9. Global Metastatic Bone Disease Market Analysis and Forecast, by End-user

10. Global Metastatic Bone Disease Market Analysis and Forecast, by Region

11. North America Metastatic Bone Disease Market Analysis and Forecast

12. Europe Metastatic Bone Disease Market Analysis and Forecast

13. Asia Pacific Metastatic Bone Disease Market Analysis and Forecast

14. Latin America Metastatic Bone Disease Market Analysis and Forecast

15. Middle East & Africa Metastatic Bone Disease Market Analysis and Forecast

16. Competition Landscape

第1章序文

第2章前提条件と調査手法

第3章エグゼクティブサマリー：世界市場

第4章市場概要

第5章重要な洞察

第6章世界市場の分析と予測：治療法別

第7章世界市場の分析と予測：転移の原因別

第8章世界市場の分析と予測：プロバイダータイプ別

第9章世界市場の分析と予測：エンドユーザー別

第10章世界市場の分析と予測：地域別

第11章北米市場の分析と予測

第12章欧州市場の分析と予測

第13章アジア太平洋市場の分析と予測

第14章ラテンアメリカ市場の分析と予測

第15章中東・アフリカ市場の分析と予測

第16章競合情勢